Home/Filings/4/0001992260-25-000008
4//SEC Filing

Randhawa Simrat 4

Accession 0001992260-25-000008

CIK 0001690585other

Filed

Nov 13, 7:00 PM ET

Accepted

Nov 14, 9:00 PM ET

Size

28.8 KB

Accession

0001992260-25-000008

Insider Transaction Report

Form 4
Period: 2025-11-13
Randhawa Simrat
EVP, Head of R&D
Transactions
  • Sale

    Common Stock

    2025-11-13$37.04/sh42,765$1,584,01622,576 total
  • Exercise/Conversion

    Common Stock

    2025-11-14$21.77/sh+37,494$816,24481,781 total
  • Exercise/Conversion

    Common Stock

    2025-11-13$17.88/sh+3,529$63,09991,507 total
  • Sale

    Common Stock

    2025-11-13$35.80/sh26,166$936,74365,341 total
  • Exercise/Conversion

    Common Stock

    2025-11-14$17.88/sh+40,287$720,33244,287 total
  • Sale

    Common Stock

    2025-11-14$38.14/sh109,031$4,158,4424,000 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-133,529116,471 total
    Exercise: $17.88Exp: 2034-01-23Common Stock (3,529 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-1437,49462,506 total
    Exercise: $21.77Exp: 2034-05-22Common Stock (37,494 underlying)
  • Exercise/Conversion

    Common Stock

    2025-11-13$8.44/sh+83,978$708,77487,978 total
  • Sale

    Common Stock

    2025-11-13$37.72/sh18,576$700,6874,000 total
  • Exercise/Conversion

    Common Stock

    2025-11-14$22.07/sh+31,250$689,688113,031 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-1383,97811,996 total
    Exercise: $8.44Exp: 2032-06-06Common Stock (83,978 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-1440,28776,184 total
    Exercise: $17.88Exp: 2034-01-23Common Stock (40,287 underlying)
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2025-11-1431,250118,750 total
    Exercise: $22.07Exp: 2035-02-03Common Stock (31,250 underlying)
Footnotes (8)
  • [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2025.
  • [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.48 to $36.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.48 to $37.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F4]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.48 to $38.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
  • [F5]The shares of common stock underlying this stock option award vested as to 25% of the shares on April 25, 2023, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  • [F6]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  • [F7]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after May 1, 2024, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
  • [F8]The shares of common stock underlying this stock option award vest in equal monthly installments over the four years after January 1, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Documents

1 file

Issuer

Dianthus Therapeutics, Inc. /DE/

CIK 0001690585

Entity typeother

Related Parties

1
  • filerCIK 0001992260

Filing Metadata

Form type
4
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 9:00 PM ET
Size
28.8 KB